To understand how the vascular complications of diabetes develop and progress and how we can target specific pathways to delay, stop or reverse diabetic micro-and macrovascular complications including heart and kidney disease.

I am Deputy Head of the Department of Diabetes at Monash University, Central Clinical School and lead the research program Diabetes and Kidney disease. I am Professor of Medicine at Monash University, the University of Hannover, Germany and have an honory affiliation with Maastricht University, the Netherlands. I hold the prestigeous Leibniz Chair for Diabetes Research at the University of Dusseldorf,Germany where I also lead a Research group in diabetic nephropathy.

My research program is considered one of the leading groups in diabetic compliactions, nephropathy and cardiovascular disease in the world.

My team was the first to describe the role of NADPH oxidases in diabetic complications. This has resulted in 6 papers in nephropathy (JASN 2014; Diabetes 2017-on front cover, and Diabetologia 2017). Furthermore, the group has published 7 papers in atherosclerosis (Circulation 2013, ATVB 2016 and Diabetologia 2014) as well as in retinopathy. Overall I have published > 170 publications in the top journals of nephrology, cardiovascular research and diabetes. My h-index is 56 and I have >10,000 citations.

I am increasingly invited to write expert reviews and editorials (> 20) and am invited to present at the major meetings in diabetes, nephrology and cardiovascular research (> 40 international invitations in the last 5 years), often as plenary or keynote lecturer.

I am currently Chief investigator on 2 NHMRC project grants and in my role as a clinician/scientist lead a clinical trial on a novel Nox inhibitor in diabetic kidney disease in type 1 diabetes. Inded, I have secrured a multimillion dollar grant from JDRF and ARC for this investigator initiated trial which is currently recruiting at 15 sites in Australia, NZ, Denmark and in Germany.

I have established many international high level collaborations (Prof R Touyz, Glasgow University, Prof H Schmidt, University of Maastricht, and Prof C Godson, University of Dublin.

I am a past president of the Australian Athersclerosis Society and serve on editorial boards for several journal: Diabetologia> 8 years, Clinical Science, PlosOne, Journal Molecular Medicine and the Australian RACP endorsed Internal Mediccine Journal.

Furthermore, I am co-chair of the BmedSc program at CCS, Monash University and have supervised > 20 Honours students and 5 PhD students to completion.

Currently we work on several programs on the role of Nox5 in diabetic complications, the role of epigenetic mechanisms in diabetic complications specifically atherosclerosis and on inflammasome inhibition in diabetic kidney disease.